Interim report July 1, 2022 – March 31, 2023
28 April, 2023
By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203.
Summary of the third quarter (2023-01-01 – 2023-03-31)
- Patient recruitment has begun for the Multiple Myeloma study
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -1,6 (-1,1)
- Earnings per share* SEK -0.08 (-0.06)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.
Summary of the nine-month period (2022-07-01 – 2023-03-31)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -3,7 (-3,2)
- Earnings per share* SEK -0.19 (-0.20)
- Cash and cash equivalents at the end of the period amounted to MSEK 27.1 (35,5)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 16,225,200. Amounts in brackets refer to the corresponding period last year.
CEO’s comment
The application for clinical phase 1 study regarding OsteoDex’s treatment of multiple myeloma was approved by the Medical Products Agency and permission was granted on August 10, 2022. The study includes 20 patients with multiple myeloma and is conducted at about 4 hospital centers in Sweden.
The principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients included have relapsed/refractory disease and have received 1-3 prior lines of therapy. The primary objective is to confirm safety and tolerability and as a secondary objective to determine treatment response documented by change in the level of disease-related biomarkers. Documentation of quality of life will also be done (QoL scores).
Study material, GMP manufactured OsteoDex, is produced by Biovian OY, Turku, Finland. Biovian is the company’s CMO. The study has started at the end of March 2023 and patient recruitment is ongoing. It is expected to be completed in Q4 2024.
Anders R Holmberg
CEO